公开(公告)号：US20190240225A1

公开(公告)日：2019-08-08

申请号：US16318925

申请日：2017-07-21

Applicant: LES LABORATOIRES SERVIER ,  NOVARTIS AG

Inventor： Andrew WEI ,  Donia MOUJALLED ,  Giovanna POMILIO ,  Ana Leticia MARAGNO ,  Olivier GENESTE ,  Audrey CLAPERON ,  Heiko MAACKE ,  Ensar HALILOVIC ,  Dale PORTER ,  Erick MORRIS ,  Youzhen WANG ,  Sneha SANGHAVI ,  Prakash MISTRY

IPC: A61K31/519 ,  A61K31/4725 ,  A61P35/02

CPC classification number: A61K31/519 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/407 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/55 ,  A61K31/675 ,  A61K45/06 ,  A61P35/02

Abstract: A combination comprising a BCL-2 inhibitor and a MCL1 inhibitor, and compositions and uses thereof.

公开(公告)号：US20180185341A1

公开(公告)日：2018-07-05

申请号：US15516443

申请日：2015-10-02

Applicant: Novartis AG

Inventor： Nicole BUSCHMANN ,  Robin Alec FAIRHURST ,  Pascal FURET ,  Diana GRAUS PORTA ,  Carolina HAEFLIGER ,  Bo HAN ,  Thomas KNÖPFEL ,  Catherine LEBLANC ,  Lv LIAO ,  Robert MAH ,  Masato MURAKAMI ,  Pierre NIMSGERN ,  Michael PALMER ,  Dale PORTER ,  Sebastien RIPOCHE ,  Can WANG ,  Youzhen WANG ,  Andreas WEISS ,  Jing XIONG ,  Xianglin ZHAO

IPC: A61K31/4375 ,  A61K31/496 ,  A61P35/00

CPC classification number: A61K31/4375 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/55 ,  A61P35/00

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof

公开(公告)号：US20210386763A1

公开(公告)日：2021-12-16

申请号：US17415985

申请日：2019-12-18

Applicant: NOVARTIS AG

Inventor： Nelson GUERREIRO ,  Ensar HALILOVIC ,  Astrid JULLION ,  Christophe MEILLE ,  Youzhen WANG

IPC: A61K31/635 ,  A61K31/506 ,  A61K45/06 ,  A61P35/02

Abstract: The present invention relates to the combination of the HDM2-p53 interaction inhibitor drug (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one [HDM201] and the BCL2 inhibitor 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(oxan-4yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide [venetoclax]. The present invention further relates to the use of said combination in the treatment of cancer, in particular hematological tumors. The present invention further relates to dose and dosing regimen related to this combination cancer treatment.

公开(公告)号：US20220016118A1

公开(公告)日：2022-01-20

申请号：US17292480

申请日：2019-11-14

Applicant: LES LABORATOIRES SERVIER ,  NOVARTIS AG

Inventor： Ensar HALILOVIC ,  Youzhen WANG ,  Erick MORRIS ,  Marina KONOPLEVA ,  Anna SKWARSKA

IPC: A61K31/519 ,  A61K31/553 ,  A61K31/706 ,  A61K31/704 ,  A61P35/02

Abstract: A combination of (a) Midostaurin, or a pharmaceutically acceptable salt thereof, or a complex thereof, or a co-crystal thereof, or a solvate, including hydrate, thereof, and (b) a Mcl-1 inhibitor and compositions and uses thereof.

公开(公告)号：US20190231760A1

公开(公告)日：2019-08-01

申请号：US16289612

申请日：2019-02-28

Applicant: NOVARTIS AG

Inventor： Nicole BUSCHMANN ,  Robin Alec FAIRHURST ,  Pascal FURET ,  Diana GRAUS PORTA ,  Carolina HAEFLIGER ,  Bo HAN ,  Thomas KNOPFEL ,  Catherine LEBLANC ,  Lv LIAO ,  Robert MAH ,  Masato MURAKAMI ,  Pierre NIMSGERN ,  Michael PALMER ,  Dale PORTER ,  Sebastien RIPOCHE ,  Can WANG ,  Youzhen WANG ,  Andreas WEISS ,  Jing XIONG ,  Xianglin ZHAO

IPC: A61K31/4375 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/55

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof